Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DBV Technologies S.A. - American Depositary Shares (NQ:DBVT)

14.25 -0.39 (-2.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DBV Technologies S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Top movers in Tuesday's session
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Combined General Meeting of June 11, 2025
From DBV Technologies S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Everus Construction Group Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Information regarding the total number of voting rights and  total number of shares of the Company as of April 30, 2025
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Reports First Quarter 2025 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
From DBV Technologies S.A.
Via GlobeNewswire
3 Biopharmaceutical Stocks Bucking the Sell-Off
Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence. 
Via MarketBeat
Topics World Trade
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why DBV Technologies (DBVT) Stock Is Skyrocketing
DBV Technologies secured up to $306.9M to advance its Viaskin Peanut program. The funding supports FDA submission, commercialization and ongoing pediatric peanut allergy treatment research. 
Via Benzinga
Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher
 
Via Benzinga
Topics Stocks
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected
 
Via Benzinga
Topics Economy
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets'
U.S. stock futures fell on Friday after two consecutive days of decline on Wednesday and Thursday. Futures of benchmark indices were lower. 
Via Benzinga
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
From DBV Technologies S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
From DBV Technologies S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study
From DBV Technologies S.A.
Via GlobeNewswire
DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids
DBV Technologies secures FDA guidance for Accelerated Approval of its Viaskin Peanut patch, advancing treatment for toddlers with peanut allergies through pivotal trials. 
Via Benzinga
Wall Street Poised To Open Lower A Day After Nasdaq's Record Close Above 20,000: Expert Flags 'Deterioration Under The Surface' As 117 S&P 500 Stocks Hit New Monthly Lows
U.S. stock futures declined on Thursday in premarket hours after hitting fresh highs on Wednesday. S&P 500, Dow, Nasdaq 100 & R2K were down. 
Via Benzinga
Topics Stocks
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
From DBV Technologies S.A.
Via GlobeNewswire
Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024
From DBV Technologies S.A.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.